Rafael Holdings Q2 net loss widens on consolidation of Cyclo Therapeutic's costs

Reuters

Mar 17

Rafael Holdings <a href="https://laohu8.com/S/QTWO">Q2</a> net loss widens on consolidation of Cyclo Therapeutic's costs

Overview

U.S. biotechnology firm's fiscal Q2 revenue rose yr/yr but remains modest
Net loss widened to $6.4 mln due to consolidation of Cyclo Therapeutic’s expenses after Cyclo acquisition
Company expects top-line results from pivotal Phase 3 trial in Q3 calendar 2026

Outlook

Company expects to complete 96-week Phase 3 Trappsol Cyclo trial and report top-line results in Q3 2026

Result Drivers

CYLO ACQUISITION IMPACT - Higher net loss and R&D expenses driven by consolidation of Cyclo Therapeutic's costs after March 2025 acquisition
LOWER ADMIN COSTS - General and administrative expenses fell due to reduced payroll and professional fees, partly offset by Cyclo expenses

Company press release: ID:nGNX8L5Qhc

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q2 Product Revenue		$125,000
Q2 Net Income		-$6.33 mln
Q2 Operating Income		-$6.66 mln

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2620499489"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2620499489\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2620499489?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-17 04:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620499489","market":"nz","top_or_hot":-1,"title":"Rafael Holdings Q2 net loss widens on consolidation of Cyclo Therapeutic's costs","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Rafael Holdings <a href=\"https://laohu8.com/S/QTWO\">Q2</a> net loss widens on consolidation of Cyclo Therapeutic's costs </title></head><body><p><span>Overview</span></p><ul><li><p>U.S. biotechnology firm's fiscal Q2 revenue rose yr/yr but remains modest</p></li><li><p>Net loss widened to $6.4 mln due to consolidation of Cyclo Therapeutic’s expenses after Cyclo acquisition</p></li><li><p>Company expects top-line results from pivotal Phase 3 trial in Q3 calendar 2026</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects to complete 96-week Phase 3 Trappsol Cyclo trial and report top-line results in Q3 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>CYLO ACQUISITION IMPACT - Higher net loss and R&amp;D expenses driven by consolidation of Cyclo Therapeutic's costs after March 2025 acquisition</p></li><li><p>LOWER ADMIN COSTS - General and administrative expenses fell due to reduced payroll and professional fees, partly offset by Cyclo expenses</p></li></ul><p>Company press release: <span>ID:nGNX8L5Qhc</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 Product Revenue</p></td><td></td><td><p>$125,000</p></td><td></td></tr><tr><td><p>Q2 Net Income</p></td><td></td><td><p>-$6.33 mln</p></td><td></td></tr><tr><td><p>Q2 Operating Income</p></td><td></td><td><p>-$6.66 mln</p></td><td></td></tr></tbody></table><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rafael Holdings Q2 net loss widens on consolidation of Cyclo Therapeutic's costs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRafael Holdings Q2 net loss widens on consolidation of Cyclo Therapeutic's costs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-17 04:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Rafael Holdings <a href=\"https://laohu8.com/S/QTWO\">Q2</a> net loss widens on consolidation of Cyclo Therapeutic's costs </title></head><body><p><span>Overview</span></p><ul><li><p>U.S. biotechnology firm's fiscal Q2 revenue rose yr/yr but remains modest</p></li><li><p>Net loss widened to $6.4 mln due to consolidation of Cyclo Therapeutic’s expenses after Cyclo acquisition</p></li><li><p>Company expects top-line results from pivotal Phase 3 trial in Q3 calendar 2026</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects to complete 96-week Phase 3 Trappsol Cyclo trial and report top-line results in Q3 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>CYLO ACQUISITION IMPACT - Higher net loss and R&amp;D expenses driven by consolidation of Cyclo Therapeutic's costs after March 2025 acquisition</p></li><li><p>LOWER ADMIN COSTS - General and administrative expenses fell due to reduced payroll and professional fees, partly offset by Cyclo expenses</p></li></ul><p>Company press release: <span>ID:nGNX8L5Qhc</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 Product Revenue</p></td><td></td><td><p>$125,000</p></td><td></td></tr><tr><td><p>Q2 Net Income</p></td><td></td><td><p>-$6.33 mln</p></td><td></td></tr><tr><td><p>Q2 Operating Income</p></td><td></td><td><p>-$6.66 mln</p></td><td></td></tr></tbody></table><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4233","symbol_name":"房地产运营公司","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nL1N40412Q:1","article_id":"2620499489","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620499489","pubTimestamp":1773691978,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Rafael Holdings Q2 net loss widens on consolidation of Cyclo Therapeutic's costsOverviewU.S. biotechnology firm's fiscal Q2 revenue rose yr/yr but remains modestNet loss widened to $6.4 mln due to con","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4233":"房地产运营公司","BK4205":"房地产经营公司","RFL":"Rafael Holdings, Inc.","BK4007":"制药"},"translate_title":"Rafael Holdings第二季度净亏损因Cyclo Therapeutic成本合并而扩大","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RFL":0.9},"content_text":"Rafael Holdings Q2 net loss widens on consolidation of Cyclo Therapeutic's costs OverviewU.S. biotechnology firm's fiscal Q2 revenue rose yr/yr but remains modestNet loss widened to $6.4 mln due to consolidation of Cyclo Therapeutic’s expenses after Cyclo acquisitionCompany expects top-line results from pivotal Phase 3 trial in Q3 calendar 2026OutlookCompany expects to complete 96-week Phase 3 Trappsol Cyclo trial and report top-line results in Q3 2026Result DriversCYLO ACQUISITION IMPACT - Higher net loss and R&D expenses driven by consolidation of Cyclo Therapeutic's costs after March 2025 acquisitionLOWER ADMIN COSTS - General and administrative expenses fell due to reduced payroll and professional fees, partly offset by Cyclo expensesCompany press release: ID:nGNX8L5QhcKey DetailsMetricBeat/MissActualConsensus EstimateQ2 Product Revenue$125,000Q2 Net Income-$6.33 mlnQ2 Operating Income-$6.66 mlnFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}